Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis

Last updated: August 25, 2024
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Overall Status: Completed

Phase

N/A

Condition

Asthma

Nasal Obstruction

Allergy

Treatment

conventional medication

Bacillus clausii tablets（Qipian®）

Clinical Study ID

NCT06573164
2024-0477
  • Ages 18-50
  • All Genders

Study Summary

Allergic rhinitis and asthma are common respiratory diseases. Qipian® is a Chinese medicine made from three types of bacteria, used to treat these conditions. This study will retrospectively analyze the effects of adding Qipian® to the regular treatment for patients with allergic rhinitis, with or without asthma. Patients meeting the Allergic Rhinitis and its Impact on Asthma（ARIA） and Global Initiative for Asthma（GINA） diagnostic criteria were divided into two groups: one receiving standard drug treatment, and the other receiving standard treatment plus Qipian®. The study will compare clinical symptoms and relevant blood markers before and after treatment to see if adding Qipian® leads to better outcomes than the standard treatment alone.This study aims to determine how Qipian® benefits patients with rhinitis and asthma and its effect on related serum indicators, helping to explore its role in allergic respiratory diseases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with rhinitis who meet the ARIA (Allergic Rhinitis and Its Impact onAsthma) guidelines.

  • Patients with asthma who meet the GINA (Global Initiative for Asthma) guidelines.

Exclusion

Exclusion Criteria:

  • Patients undergoing combined dust mite-specific immunotherapy

  • Patients undergoing combined treatment with biologics, including omalizumab,dupilumab, or mepolizumab.

  • Patients undergoing combined treatment with small molecule drugs, includingupadacitinib, abrocitinib, baricitinib, and other JAK inhibitors.

  • Patients who are unwilling to comply with treatment, are unable to adhere to regularmedication schedules, and do not attend follow-up appointments.

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: conventional medication
Phase:
Study Start date:
January 01, 2024
Estimated Completion Date:
July 31, 2024

Study Description

Allergic rhinitis and asthma are common chronic respiratory diseases, with rising prevalence each year. Bacterial lysates (BLs) are a potential treatment option that has been used for over 100 years. Qipian® is a Chinese medication containing extracts from three types of bacteria, used to treat chronic respiratory diseases. It effectively alleviates symptoms and improves the immune system. This study will retrospectively analyze the clinical efficacy of adding Qipian® to the conventional drug treatment in patients with allergic rhinitis with or without asthma. Patients diagnosed with rhinitis and asthma according to ARIA and GINA guidelines were included in the study. They will be divided into two groups based on their treatment regimen: a conventional drug treatment group and a conventional drug plus Qipian® treatment group. Clinical symptoms and relevant serum markers were collected to assess changes before and after treatment, and to determine whether the addition of Qipian® results in more significant improvements compared to the conventional drug treatment group. This will help determine the benefits of Qipian® for patients with rhinitis, with or without asthma, in terms of clinical symptoms and serum indicators, and further explore its role in allergic respiratory diseases.

Connect with a study center

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang 310009
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.